Advanced Translational Research on Childhood Leukemia
Driving Therapeutic Progress of Childhood Leukemia Through Advanced Translational Research With Immediate and Long-term Impact. Precision Medicine for Childhood Leukemia.
Chinese University of Hong Kong
300 participants
Jul 1, 2020
OBSERVATIONAL
Conditions
Summary
Prognosis of children with leukemia, the most common pediatric cancer, has improved markedly. Yet, relapse still occurs in 15-40% of patients with a probability of survival of \<50%, which is unlikely to be boosted by intensification of standard chemotherapy due to overwhelming toxicity. The advent of effective and safe targeted therapies for high-risk cases is therefore imperative. This study constitutes two research projects aiming at driving therapeutic advances.
Eligibility
Inclusion Criteria6
- acute lymphoblastic leukemia (ALL) or
- acute myeloid leukemia (AML) or
- mixed phenotype acute leukemia (MPAL) or
- \. juvenile myelomonocytic leukemia (JMML) or
- \. myelodysplastic syndromes (MDS) or
- \. normal bone marrow donor
Exclusion Criteria2
- This study will not recruit subjects who are unable to understand English or Chinese.
- Patient or parent refusal
Interventions
Gene expression and fusion transcripts analysis
Genetic alternation analysis
Remission and relapse are monitored by cytogenetic analyses.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04478006